Profile data is unavailable for this security.
About the company
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
- Revenue in CAD (TTM)1.85m
- Net income in CAD-1.95m
- Incorporated2003
- Employees--
- LocationArch Biopartners Inc27 St. Clair Ave E.,P.O. Box 305TORONTO M4T 2M5CanadaCAN
- Phone+1 (647) 428-7031
- Fax+1 (647) 351-3565
- Websitehttps://archbiopartners.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KDA Group Inc | 186.28k | 133.66k | 69.24m | -- | 196.52 | 4.46 | 79.25 | 371.68 | 0.002 | 0.0926 | 0.0012 | 0.0886 | 0.0079 | -- | 0.0693 | -- | -0.4146 | -17.96 | -0.8534 | -44.69 | 36.51 | 26.76 | -52.24 | -28.00 | -- | -4.31 | 0.1287 | -- | -22.20 | -62.03 | 106.88 | -- | 31.67 | -- |
| Cannara Biotech Inc | 73.38m | 6.22m | 72.87m | -- | 11.66 | 0.919 | 6.13 | 0.993 | 0.0695 | 0.0695 | 0.8173 | 0.8814 | 0.5337 | 2.08 | 7.46 | -- | 4.52 | -4.46 | 6.23 | -4.95 | 10.06 | 17.86 | 8.48 | -15.88 | 0.3582 | -2.46 | 0.384 | -- | 59.91 | -- | 201.26 | -- | -- | -- |
| ZYUS Life Sciences Corp | 351.00k | -42.59m | 73.63m | 2.00 | -- | 3.19 | -- | 209.78 | -0.639 | -0.639 | 0.0058 | 0.3263 | 0.0066 | 0.0577 | 0.8069 | -- | -80.10 | -57.88 | -108.06 | -71.19 | 48.72 | -16.16 | -12,134.19 | -10,367.37 | 0.5547 | -4.56 | 0.2979 | -- | 17.79 | 213.99 | -72.73 | -- | -- | -- |
| Theratechnologies Inc | 106.29m | -24.49m | 81.38m | 89.00 | -- | -- | -- | 0.7657 | -0.8431 | -0.8431 | 3.26 | -0.7282 | 1.03 | 1.89 | 7.81 | -- | -23.78 | -26.32 | -128.23 | -55.43 | 74.10 | 65.90 | -23.04 | -38.26 | 1.03 | -0.919 | 1.71 | -- | 2.13 | 12.58 | 49.28 | -- | -37.83 | -- |
| Sernova Corp | 0.00 | -40.73m | 97.03m | -- | -- | 25.32 | -- | -- | -0.1343 | -0.1343 | 0.00 | 0.0126 | 0.00 | -- | -- | -- | -124.29 | -74.84 | -180.95 | -85.03 | -- | -- | -- | -- | -- | -- | 0.142 | -- | -- | -- | -59.69 | -- | -2.91 | -- |
| Biosyent Inc | 31.59m | 6.46m | 106.17m | 0.00 | 16.92 | 3.04 | 15.35 | 3.36 | 0.5319 | 0.5319 | 2.60 | 2.96 | 0.7704 | 1.15 | 10.12 | -- | 15.75 | 14.77 | 18.26 | 16.92 | 81.03 | 79.74 | 20.45 | 19.99 | 5.42 | -- | 0.0339 | 9.26 | 13.12 | 7.97 | 18.35 | 2.52 | -2.67 | -- |
| Arch Biopartners Inc | 1.85m | -1.95m | 106.78m | -- | -- | -- | -- | 57.81 | -0.0312 | -0.0312 | 0.0296 | -0.091 | 2.73 | -- | 4.38 | -- | -288.23 | -214.82 | -- | -- | -- | -- | -105.69 | -180.45 | -- | -3.94 | -- | -- | 105.63 | -- | -136.30 | -- | -- | -- |
| Oncolytics Biotech Inc | 0.00 | -28.21m | 113.88m | 29.00 | -- | 4.96 | -- | -- | -0.4027 | -0.4027 | 0.00 | 0.3046 | 0.00 | -- | -- | -- | -80.51 | -81.99 | -88.84 | -97.25 | -- | -- | -- | -- | -- | -- | 0.0468 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
| Spectral Medical Inc | 1.74m | -17.93m | 139.23m | 29.00 | -- | -- | -- | 80.20 | -0.0643 | -0.0647 | 0.0062 | -0.0721 | 0.2507 | 3.23 | 2.19 | 59,862.07 | -258.89 | -109.65 | -18,581.35 | -175.35 | 37.85 | 63.74 | -1,032.89 | -445.72 | 0.3287 | -2.56 | -- | -- | -4.14 | -16.08 | -104.12 | -- | 31.53 | -- |
| Eupraxia Pharmaceuticals Inc | 0.00 | -41.64m | 142.40m | 29.00 | -- | 5.36 | -- | -- | -1.65 | -1.65 | 0.00 | 0.7467 | 0.00 | -- | -- | 0.00 | -122.29 | -127.84 | -185.74 | -935.99 | -- | -- | -- | -- | -- | -85.63 | 0.3455 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
